Transplanting rejuvenated blood stem cells extends lifespan of aged immunocompromised mice
Sara Montserrat-Vazquez,Sara Montserrat-Vazquez,Noelle J. Ali,Francesca Matteini,Francesca Matteini,Javier Lozano,Javier Lozano,Tu Zhaowei,Eva Mejia-Ramirez,Eva Mejia-Ramirez,Eva Mejia-Ramirez,Gina Marka,Angelika Vollmer,Karin Soller,Mehmet Sacma,Vadim Sakk,Loris Mularoni,Jan Philipp Mallm,Mireya Plass,Mireya Plass,Mireya Plass,Yi Zheng,Hartmut Geiger,M. Carolina Florian,M. Carolina Florian,M. Carolina Florian
DOI: https://doi.org/10.1038/s41536-022-00275-y
IF: 14.404
2022-12-29
npj Regenerative Medicine
Abstract:One goal of regenerative medicine is to rejuvenate tissues and extend lifespan by restoring the function of endogenous aged stem cells. However, evidence that somatic stem cells can be targeted in vivo to extend lifespan is still lacking. Here, we demonstrate that after a short systemic treatment with a specific inhibitor of the small RhoGTPase Cdc42 (CASIN), transplanting aged hematopoietic stem cells (HSCs) from treated mice is sufficient to extend the healthspan and lifespan of aged immunocompromised mice without additional treatment. In detail, we show that systemic CASIN treatment improves strength and endurance of aged mice by increasing the myogenic regenerative potential of aged skeletal muscle stem cells. Further, we show that CASIN modifies niche localization and H4K16ac polarity of HSCs in vivo. Single-cell profiling reveals changes in HSC transcriptome, which underlie enhanced lymphoid and regenerative capacity in serial transplantation assays. Overall, we provide proof-of-concept evidence that a short systemic treatment to decrease Cdc42 activity improves the regenerative capacity of different endogenous aged stem cells in vivo, and that rejuvenated HSCs exert a broad systemic effect sufficient to extend murine health- and lifespan.
cell & tissue engineering,engineering, biomedical